candesartan has been researched along with Nervous System Diseases in 3 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we investigated the effect of postischemic treatment using the angiotensin II type 1 receptor blocker, candesartan, on brain damage in focal cerebral ischemia." | 3.75 | Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. ( Kitagawa, K; Okazaki, S; Omura-Matsuoka, E; Oyama, N; Sakoda, S; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2009) |
| "Candesartan is an angiotensin II-receptor blocker and has proved neuroprotective properties." | 1.72 | Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress. ( Abo-Saif, MA; Khedr, NF; Werida, RH, 2022) |
| "pretreatment with candesartan, 0." | 1.32 | Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. ( Blume, A; Culman, J; Gohlke, P; Groth, W; Unger, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Khedr, NF | 1 |
| Werida, RH | 1 |
| Abo-Saif, MA | 1 |
| Omura-Matsuoka, E | 1 |
| Yagita, Y | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Oyama, N | 1 |
| Sugiyama, Y | 1 |
| Okazaki, S | 1 |
| Sakoda, S | 1 |
| Kitagawa, K | 1 |
| Groth, W | 1 |
| Blume, A | 1 |
| Gohlke, P | 1 |
| Unger, T | 1 |
| Culman, J | 1 |
3 other studies available for candesartan and Nervous System Diseases
| Article | Year |
|---|---|
Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress.
Topics: Animals; Autophagy; Autophagy-Related Protein 5; Beclin-1; Benzimidazoles; Biphenyl Compounds; Galac | 2022 |
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2009 |
Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2003 |